The Janssen Pharmaceutical Companies of Johnson & Johnson has unveiled its campaign on mental health awareness titled ‘All Minds Matter’. The campaign earlier focussed on schizophrenia, and is now including Attention Deficit Hyperactivity Disorder (ADHD) in its approach to promote mental health well-being.
The film focuses on three people – they are shown to be easily distracted, inattentive and find focusing on one task difficult. They have suffered all their lives for ‘being different’ and keep wondering how they can improve the quality of their lives.
To shed light on the varying mental health issues, specifically schizophrenia, the company launched the ‘All Minds Matter’ campaign in April 2022. The campaign strove to drive awareness, initiate dialogue, and enhance the quality of life for patients and caregivers grappling with schizophrenia.
The company is now focusing on ADHD. Although, initially regarded as a childhood condition, evidence states that ADHD, being a neurodevelopmental disorder, persists into adulthood although the symptoms may be somewhat modified with age.
ADHD is recognised by attention deficit, hyperactivity, and impulsiveness and influences multiple facets of daily life, from education to relationships and work. According to several studies, globally less than 20 pc of adults suffering from ADHD are aware of their condition, while in India, about 14 pc of the population is known to be battling ADHD – a neurodevelopmental disorder affecting emotional well-being. Many affected by ADHD battle internal misconceptions, believing it’s an unfixable flaw, leading to untreated ADHD and a cycle of self-doubt.
“We are committed to fostering a society where mental health is accepted, understood, and supported, regardless of the specific condition. Extending our campaign to encompass ADHD is a natural evolution of our ongoing mission to eliminate stigma, raise awareness, and enhance the lives of individuals facing mental health challenges,” said Dr Jitendra Dixit, Head of Medical Affairs, Janssen India.
Feedback: [email protected]
